Lake Street reiterates a Buy rating and $12 price target on NeuroPace (NPCE), telling investors that the firm continues to think shares have room for continued outperformance in 2024 despite “a big move” in 2023. The firm thinks the right infrastructure is in place for 2024 to drive continued growth with minimal incremental opex, resulting in improving leverage, and thinks NeuroPace can likely continue to benefit from a delayed post-Covid reopening and share-taking from LivaNova (LIVN) and Medtronic (MDT), the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NPCE:
- NeuroPace announces early completion of patient enrollment in NAUTILUS study
- NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
- NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
- NeuroPace price target raised to $9 from $8 at Morgan Stanley
